Ignite Creation Date:
2024-07-17 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06467539
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-06-16
Brief Title:
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Sponsor:
Chang Gung Memorial Hospital
Organization:
Chang Gung Memorial Hospital
Study Overview
Official Title:
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia In addition several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None